Filing Flows › Cumberland Pharmaceuticals (CPIX) › Q2 2026 › vs Q1 2026
Cumberland Pharmaceuticals (CPIX) Q2 2026 vs Q1 2026 (quarter over quarter)
Cumberland Pharmaceuticals's revenue fell $330K (-4%) from $9.1M in Q1 2026 to $8.8M in Q2 2026. The biggest changes: Sancuso −$1.1M (-38%); Caldolor +$509K (+53%); Talicia +$433K (+23%).
Cumberland Pharmaceuticals, Q2 2026: revenue $8.8M (-19% year over year), operating margin -35.9%, net loss $4.3M, operating cash flow $169K. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 1.5% | 4.2% | -2.8 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Talicia | $2.3M | $1.9M | $433K | +23% |
| Sancuso | $1.8M | $2.9M | −$1.1M | -38% |
| Vibativ | $1.7M | $2.1M | −$379K | -18% |
| Caldolor | $1.5M | $966K | $509K | +53% |
| Kristalose | $1.1M | $981K | $80K | +8% |
| Other revenue | $222K | $169K | $53K | +31% |
| Acetadote | $137K | $52K | $85K | +163% |
| Revenue | $8.8M | $9.1M | −$330K | -4% |
| Net loss | $4.3M | $3.3M | $987K | +30% |
| Costs & expenses | $13.1M | $12.4M | $657K | +5% |
| Operating costs | $12.0M | $12.3M | −$299K | -2% |
| Interest & other, net | $1.1M | $154K | $956K | +621% |
| Income tax | $4K | $4K | −$1 | 0% |
| Research & development | $772K | $1.5M | −$686K | -47% |
| General & admin | $2.5M | $2.6M | −$7K | -0.3% |
| Other operating costs | $8.6M | $1.2M | $7.4M | +592% |
| Operating cash sources | $4.4M | $2.4M | $2.0M | +85% |
| Share-based compensation | $78K | $107K | −$29K | -27% |
| Working capital & other | $4.4M | $2.3M | $2.1M | +91% |
| Net loss absorbed | $4.3M | $3.3M | $987K | +30% |
| Operating cash flow | $169K | $387K | −$218K | -56% |
| Free cash flow (OCF − capex) | $130K | $387K | −$257K | -66% |
| Capital expenditures | $38K | $0 | $38K | — |
Questions
How much did Cumberland Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Cumberland Pharmaceuticals's revenue fell $330K (-4%) from $9.1M in Q1 2026 to $8.8M in Q2 2026.
What drove Cumberland Pharmaceuticals's revenue change in Q2 2026?
Sancuso −$1.1M (-38%); Caldolor +$509K (+53%); Talicia +$433K (+23%).